About Matthew Schiewer
- Deficiencies in the repair of DNA are a hallmark of cancer. A molecule, named PARP, is involved in DNA damage repair. The inhibition of PARP with specific medications is a potential therapy for advanced, metastatic prostate cancer.
- Inhibition of PARP may also reduce cancer progression by reducing the activity of the androgen receptor which is the engine of prostate cancer.
- In these investigations, Dr. Schiewer will study the role of PARP in the modulation of AR activity.
What this means to patients: Understanding the relationship between PARP inhibition and AR activity may provide new therapeutic opportunities for prostate cancer patients with advanced, metastatic disease.
2013 Ben Franklin-PCF Young Investigator
Matthew Schiewer, PhD
Thomas Jefferson University
Karen Knudsen, PhD
Determining the translation capacity of the PARP-1/AR axis in prostate cancer